DOCSLIB.ORG

Association of Pharmacological Treatments with Long-Term Pain Control in Patients with Knee Osteoarthritis: a Systematic Review and Meta-Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association of Pharmacological Treatments with Long-Term Pain Control in Patients with Knee Osteoarthritis: a Systematic Review and Meta-Analysis Supplementary Online Content Gregori D, Giacovelli G, Minto C, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. doi:10.1001/jama.2018.19319 eTable 1A. Final search strategy for PubMed eTable 1B. Final search strategy for Scopus eTable 1C. Final search strategy for Embase eTable 1D. Final search strategy for Web of Science eTable 1E. Final search strategy for Cochrane Central Register of Controlled Trials eTable 2. Hierarchy of tools for patient-reported outcomes assessment eTable 3. Pain (primary outcome): league table – when trials at high risk of bias were excluded eTable 4. Pain (primary outcome): league table – All trials eTable 5. Physical function (secondary outcome): league table eTable 6. Physical function (secondary outcome): summary table of results when trials at high risk of bias were excluded eTable 7. Joint space narrowing (secondary outcome): summary table of results reported as Mean Difference (in mm) and as Standardized Mean Difference eTable 8. Joint space narrowing (secondary outcome): league table eTable 9. Joint space narrowing (secondary outcome): summary table of results when trials at high risk of bias were excluded eTable 10A. Summary of results for the sensitivity analyses, including clinical and statistical sensitivities eTable 10B1. Post-hoc sensitivity analysis using a Fixed effect model instead of the Random effect model used as main analysis eTable 10B2. Post-hoc sensitivity analysis using an empirical informative prior instead of the uninformative prior used as main analysis eFigure 1A. Pain (primary outcome): Network plot - All trials eFigure 1B. Pain (primary outcome): Network plot when trials at high risk of bias were excluded eFigure 2. Pain (primary outcome): Forest plot (estimates as Standardized Mean Difference) - All trials eFigure 3. Pain (primary outcome): Forest plot (estimates as Standardized Mean Difference) when trials at high risk of bias were excluded eFigure 4A. Pain (primary outcome): SUCRA plots when trials at high risk of bias were excluded eFigure 4B. Pain (primary outcome): rankogram plots when trials at high risk of bias were excluded @2018 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 eFigure 4C. Pain (primary outcome): ranking forest plot when trials at high risk of bias were excluded eFigure 5. Pain (primary outcome): SUCRA forest plot – All trials eFigure 5A. Pain (primary outcome): SUCRA plots – All trials eFigure 5B. Pain (primary outcome): rankogram plots – All trials eFigure 5C. Pain (primary outcome): ranking forest plot – All trials eFigure 6. Network plot for comparisons on the secondary outcome physical function eFigure 7. Physical Function (secondary outcome): Forest plot eFigure 8. Physical function (secondary outcome): SUCRA forest plot eFigure 8A. Physical function (secondary outcome): SUCRA plots eFigure 8B. Physical function (secondary outcome): rankogram plots eFigure 8C. Physical function (secondary outcome): ranking forest plot eFigure 9. Network plot for comparisons on the secondary outcome joint space narrowing eFigure 10. Joint space narrowing (secondary outcome): Forest plot eFigure 11. Joint space narrowing (secondary outcome): SUCRA forest plot eFigure 11A. Joint space narrowing (secondary outcome): SUCRA plots eFigure 11B. Joint space narrowing (secondary outcome): rankogram plots eFigure 11C. Joint space narrowing (secondary outcome): ranking forest plot This supplementary material has been provided by the authors to give readers additional information about their work. @2018 American Medical Association. All rights reserved. 2 Downloaded From: https://jamanetwork.com/ on 09/23/2021 485 Search strategy: eTables 1 486 eTable 1A - Final search strategy for PubMed #ID Topic or intervention Query Records #1 Disease ("Osteoarthritis, Knee"[Mesh]) OR ("Osteoarthritis"[Mesh] AND "Knee 38927 Joint"[Mesh]) OR ("Osteoarthritis"[Mesh] AND (Knee[Title/Abstract] OR Knees[Title/Abstract])) OR ((Osteoarthritis[Title/Abstract] OR Osteoarthritides[Title/Abstract] OR Arthritis[Title/Abstract] OR Arthritides[Title/Abstract]) AND "Knee Joint"[Mesh]) OR ("Knee Osteoarthritis"[Title/Abstract] OR "Knee Osteoarthritides"[Title/Abstract] OR "Osteoarthritis of Knee"[Title/Abstract] OR "Osteoarthritis of Knees"[Title/Abstract] OR "Knee OA"[Title/Abstract] OR "Knees OA"[Title/Abstract]) OR ((Osteoarthritis[Title/Abstract] OR Osteoarthritides[Title/Abstract] OR Arthritis[Title/Abstract] OR Arthritides[Title/Abstract]) AND (Knee[Title/Abstract] OR Knees[Title/Abstract])) #2 Study design "Randomized Controlled Trial" [Publication Type] OR 735467 Randomized[Title/Abstract] OR Randomised[Title/Abstract] OR Randomization[Title/Abstract] OR Randomisation[Title/Abstract] #3 Aceclofenac "aceclofenac" [Supplementary Concept] OR Aceclofenac[Title/Abstract] 15 OR Falcol[Title/Abstract] OR "Clanza CR"[Title/Abstract] OR Preservex[Title/Abstract] OR Biofenac[Title/Abstract] OR Sanein[Title/Abstract] OR Beofenac[Title/Abstract] OR Aital[Title/Abstract] OR Airtal[Title/Abstract] OR Bristaflam[Title/Abstract] OR Gerbin[Title/Abstract] #4 Acetaminophen "Acetaminophen"[Mesh] OR Acetaminophen[Title/Abstract] OR 178 Hydroxyacetanilide[Title/Abstract] OR APAP[Title/Abstract] OR Acetamidophenol[Title/Abstract] OR Paracetamol[Title/Abstract] OR Acephen[Title/Abstract] OR Acetaco[Title/Abstract] OR Tylenol[Title/Abstract] OR "Anacin-3"[Title/Abstract] OR "Anacin 3"[Title/Abstract] OR Anacin3[Title/Abstract] OR Datril[Title/Abstract] OR Panadol[Title/Abstract] OR Acamol[Title/Abstract] OR Algotropyl[Title/Abstract] #5 Androstenedione "Androstenedione"[Mesh] OR Androstenedione[Title/Abstract] OR 0 Androstene[Title/Abstract] #6 ASA "Aspirin"[Mesh] OR Aspirin[Title/Abstract] OR "Acetylsalicylic Acid"[Title/Abstract] OR Acylpyrin[Title/Abstract] OR 31 Aloxiprimum[Title/Abstract] OR Colfarit[Title/Abstract] OR Dispril[Title/Abstract] OR Easprin[Title/Abstract] OR Ecotrin[Title/Abstract] OR Endosprin[Title/Abstract] OR Magnecyl[Title/Abstract] OR Micristin[Title/Abstract] OR Polopirin[Title/Abstract] OR Polopiryna[Title/Abstract] OR Solprin[Title/Abstract] OR Solupsan[Title/Abstract] OR Zorprin[Title/Abstract] OR Acetysal[Title/Abstract] #7 Benoxaprofen "benoxaprofen" [Supplementary Concept] OR 2 Benoxaprofen[Title/Abstract] OR Oraflex[Title/Abstract] #8 Betamethasone "Betamethasone"[Mesh] OR Betamethasone[Title/Abstract] OR 15 Flubenisolone[Title/Abstract] OR Betadexamethasone[Title/Abstract] OR 15 Celestona[Title/Abstract] OR Cellestoderm[Title/Abstract] OR Celeston[Title/Abstract] OR Celestone[Title/Abstract] #9 Calcitonin "Calcitonin"[Mesh] OR Calcitonin[Title/Abstract] OR Calcitrin[Title/Abstract] OR Thyrocalcitonin[Title/Abstract] OR "Ciba 11 47175-BA"[Title/Abstract] OR "Ciba 47175 BA"[Title/Abstract] OR "Ciba 47175BA"[Title/Abstract] #10 Capsaicin "Capsaicin"[Mesh] OR Capsaicin[Title/Abstract] OR Capsaicine[Title/Abstract] OR Axsain[Title/Abstract] OR 9 Zacin[Title/Abstract] OR Capsidol[Title/Abstract] OR Zostrix[Title/Abstract] OR Capzasin[Title/Abstract] OR Gelcen[Title/Abstract] OR Katrum[Title/Abstract] OR "Capsicum @2018 American Medical Association. All rights reserved. 3 Downloaded From: https://jamanetwork.com/ on 09/23/2021 #ID Topic or intervention Query Records Farmaya"[Title/Abstract] OR Capsin[Title/Abstract] #11 Celecoxib "Celecoxib"[Mesh] OR Celecoxib[Title/Abstract] OR 120 Celebrex[Title/Abstract] #12 Chondroitin "Chondroitin Sulfates"[Mesh] OR "Chondroitin Sulfate"[Title/Abstract] 124 OR Chondroitin[Title/Abstract] OR Chonsurid[Title/Abstract] OR Translagen[Title/Abstract] OR Blutal[Title/Abstract] #13 Cindunistat "cindunistat"[Supplementary Concept] OR Cindunistat[Title/Abstract] 1 #14 Cortivazol "cortivazol"[Supplementary Concept] OR Cortivazol[Title/Abstract] 1 #15 Dexamethasone "Dexamethasone"[Mesh] OR Dexamethasone[Title/Abstract] OR 12 Methylfluorprednisolone[Title/Abstract] OR Hexadecadrol[Title/Abstract] OR Decameth[Title/Abstract] OR Decaspray[Title/Abstract] OR Dexasone[Title/Abstract] OR Dexpak[Title/Abstract] OR Maxidex[Title/Abstract] OR Millicorten[Title/Abstract] OR Oradexon[Title/Abstract] OR Decaject[Title/Abstract] OR Hexadrol[Title/Abstract] #16 Diacerein "diacetylrhein" [Supplementary Concept] OR Diacerein[Title/Abstract] 29 OR Diacerhein[Title/Abstract] OR Diacetylrhein[Title/Abstract] OR "Diacetyl-rhein"[Title/Abstract] OR Zondar[Title/Abstract] #17 Diclofenac "Diclofenac"[Mesh] OR Diclofenac[Title/Abstract] OR 211 Diclophenac[Title/Abstract] OR Dicrofenac[Title/Abstract] OR Dichlofenal[Title/Abstract] OR "Diclonate P"[Title/Abstract] OR Feloran[Title/Abstract] OR Voltarol[Title/Abstract] OR Novapirina[Title/Abstract] OR Orthofen[Title/Abstract] OR Ortofen[Title/Abstract] OR Orthophen[Title/Abstract] OR Voltaren[Title/Abstract] #18 Diflunisal "Diflunisal"[Mesh] OR Diflunisal[Title/Abstract] OR 7 Dolobid[Title/Abstract] OR Dolocid[Title/Abstract] OR Dolobis[Title/Abstract] OR NuDifunisal[Title/Abstract] OR NovoDiflunisal[Title/Abstract] OR ApoDiflunisal[Title/Abstract] #19 Doxycycline "Doxycycline"[Mesh] OR Doxycycline[Title/Abstract] OR "Alpha-6- 17 Deoxyoxytetracycline"[Title/Abstract] OR "Alpha 6 Deoxyoxytetracycline"[Title/Abstract] OR Oracea[Title/Abstract] OR Periostat[Title/Abstract] OR "Vibra-Tabs"[Title/Abstract] OR "Vibra Tabs"[Title/Abstract] OR VibraTabs[Title/Abstract] OR Vibramycin[Title/Abstract] OR Vibravenos[Title/Abstract] OR Atridox[Title/Abstract] OR Doryx[Title/Abstract]
Load more

Recommended publications
  • Prescription Pattern of Primary Osteoarthritis in Tertiary Medical
    Published online: 2020-04-21 Running title: Primary Osteoarthritis Nitte University Journal of Health Science Original Article Prescription Pattern of Primary Osteoarthritis in Tertiary Medical Centre Sowmya Sham Kanneppady1, Sham Kishor Kanneppady2, Vijaya Raghavan3, Aung Myo Oo4, Ohn Mar Lwin5 1Senior Lecturer and Head, Department of Pharmacology, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 2Senior Lecturer, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia, 3Head of the Department of Pharmacology, KVG Medical College and Hospital, Kurunjibag, Sullia, Karnataka, India. 4Assistant Professor, Department of Biochemistry, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 5Post graduate student, Department of Physiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. *Corresponding Author : Sowmya Sham Kanneppady, Senior Lecturer and Head,Department of Pharmacology, Faculty of Medicine, Lincoln University College, No. 2, Jalan Stadium, SS 7/15, Kelana Jaya, 47301, Petaling Jaya, Selangor Darul Ehsan, Malaysia. E-mail : [email protected]. Received : 12.10.2017 Abstract Review Completed : 05.12.2017 Objectives: Osteoarthritis (OA) is one of the commonest joint/musculoskeletal disorders, Accepted : 06.12.2017 affecting the middle aged and elderly, although younger people may be affected as a result of injury or overuse. The study aimed to analyze the data, evaluate the prescription pattern and Keywords: Osteoarthritis, anti- rationality of the use of drugs in the treatment of primary OA with due emphasis on the inflammatory agents, prevalence available treatment regimens. Materials and methods: Medical case records of patients suffering from primary OA attending Access this article online the department of Orthopedics of a tertiary medical centre were the source of data.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Compound Isolated from the Cock's Comb and Its Effect on Palmar Arsenical Keratosis
    | Clinical | Trial | Compound isolated from the cock’s comb and its effect on palmar arsenical keratosis Hazera Sharmin and Mir Misbahuddin Article Info Abstract Division of Arsenic Research, This study was conducted to confirm the effectiveness of the ointment containing cock’s comb Department of Pharmacology, Faculty of extract and to identify the compound that was effective in the treatment of palmar arsenical Basic Science and Paraclinical Science, Bangabandhu Sheikh Mujib Medical keratosis. On the basis of inclusion and exclusion criteria, 24 patients with moderate to severe University, Shahbag, Dhaka, Bangladesh palmar arsenical keratosis were enrolled from an arsenic endemic area. The ointment prepared from the cock’s comb extract was supplied to each patient at an interval of 2 weeks. Each patient For Correspondence: was advised to apply the ointment on the nodule by rubbing gently up to 5 minutes and twice Mir Misbahuddin daily for 12 weeks. Improvement was monitored by measuring the nodular size before starting [email protected] and after completion of the treatment. The mean (± SD) size of the nodules of the palm before Received: 2 October 2019 treatment was 16.6 ± 5.0 mm2, which was reduced to 4.0 ± 3.8 mm2 after completion of the Accepted: 7 January 2020 treatment. This reduction was statistically significant. To identify the effective compound nuclear Available Online: 19 February 2020 magnetic resonance spectroscopy, infrared spectrophotometry, elemental analysis and liquid chromatography-mass spectroscopy of the extract were done yet conclusion could not be achieved. ISSN: 2224‐7750 (Online) 2074‐2908 (Print) DOI: 10.3329/bsmmuj.v13i1.45244 Introduction beneficial effect of the cock’s comb extract and Keywords: Arsenic; Cock‘s comb; to identify the compound that was effective in Keratosis; Palm Arsenical keratosis is not only a health problem the treatment of palmar arsenical keratosis.
    [Show full text]
  • Acid Sustained Release Tablets with Water-Insoluble Gel
    '1. j Available online at www.sciencedirect.com -.._ ~. - SCll!NCl!@DIRl!CT• 1 : Ü. Kiitüphane v;;ö 1 k ILFARMACO ELSEVIER ;' No M'-ttt-15. .. II Farmaco 58 (2003) 397 - 401 www.elsevier.com/locate/farmac • . ... ····· ····· ..... acid sustained release tablets with water-insoluble gel S. Güngör *, A. Y. Özsoy, E. Cevher, A. Araman Faculty of Pharmacy, Department of Pharmaceutical Technology, /stanbul Istanbul, Turkey Received 24 April 2002; accepted 28 November 2002 Abstract Mefenamic acid (MA) has analgesic, anti-inflammatory and antipyretic properties. Available conventional dosage forms are capsules and film-coated tablets. No commercial sustained release preparation of MA exists in the market. The usual oral dose is 250 or 500 mg and reported half-life is 2 h. Sodium alginate (NaAL) is the sodium salt of alginic acid, a natura! polysaccharide extracted from marine brown algae. it has the ability to forma water-insoluble gel with a bivalent metal ions as calcium. Therefore, NaAL has been studied for preparing sustained release formulations in pharmaceutical technology. In this study, tablet formulations containing different ratios of NaAL and calcium gluconate (CaGL) were prepared by direct compression method. In vitro release studies were carried out using USP 23 basket method and release data were kinetically evaluated. According to release studies, it can be emphasized that NaAL and CaGL can be used for design of sustained release preparation of MA. © 2003 Editions scientifiques et medicales Elsevier SAS. Ali rights reserved. Mefenamic acid; Sodium alginate; Calcium g]uconate; Sustained release 1. Introduction dispersing agent and gelation agent (10]. NaAL has the ability of forming rapid viscous solutions and gels by its Mefenamic acid (MA), 2-((2,3-dimethylphenyl)ami- contacts with aqueous media.
    [Show full text]
  • Dietary Supplements for Osteoarthritis Philip J
    Dietary Supplements for Osteoarthritis PHILIP J. GREGORY, PharmD; MORGAN SPERRY, PharmD; and AmY FRIEdmAN WILSON, PharmD Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska A large number of dietary supplements are promoted to patients with osteoarthritis and as many as one third of those patients have used a supplement to treat their condition. Glucosamine-containing supplements are among the most commonly used products for osteo- arthritis. Although the evidence is not entirely consistent, most research suggests that glucos- amine sulfate can improve symptoms of pain related to osteoarthritis, as well as slow disease progression in patients with osteoarthritis of the knee. Chondroitin sulfate also appears to reduce osteoarthritis symptoms and is often combined with glucosamine, but there is no reliable evi- dence that the combination is more effective than either agent alone. S-adenosylmethionine may reduce pain but high costs and product quality issues limit its use. Several other supplements are promoted for treating osteoarthritis, such as methylsulfonylmethane, Harpagophytum pro- cumbens (devil’s claw), Curcuma longa (turmeric), and Zingiber officinale (ginger), but there is insufficient reliable evidence regarding long-term safety or effectiveness. Am( Fam Physician. 2008;77(2):177-184. Copyright © 2008 American Academy of Family Physicians.) ietary supplements, commonly glycosaminoglycans, which are found in referred to as natural medicines, synovial fluid, ligaments, and other joint herbal medicines, or alternative structures. Exogenous glucosamine is derived medicines, account for nearly from marine exoskeletons or produced syn- D $20 billion in U.S. sales annually.1 These thetically. Exogenous glucosamine may have products have a unique regulatory status that anti-inflammatory effects and is thought to allows them to be marketed with little or no stimulate metabolism of chondrocytes.4 credible scientific research.
    [Show full text]
  • Dieses Dokument Ist Eine Zweitveröffentlichung (Verlagsversion) / This Is a Self-Archiving Document (Published Version)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Technische Universität Dresden: Qucosa Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / This is a self-archiving document (published version): Jan Gaertner, Ulrike M. Stamer, Constanze Remi, Raymond Voltz, Claudia Bausewein, Rainer Sabatowski, Stefan Wirz, Gabriele Müller-Mundt, Steffen T. Simon, Anne Pralong, Friedemann Nauck, Markus Follmann, Lukas Radbruch, Winfried Meißner Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice Erstveröffentlichung in / First published in: Palliative Medicine. 2017, 31(1), S. 26 – 34 [Zugriff am: 19.08.2019]. SAGE journals. ISSN 1477- 030X. DOI: https://doi.org/10.1177/0269216316655746 Diese Version ist verfügbar / This version is available on: https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-353637 „Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. Nationallizenz frei zugänglich.“ This publication is openly accessible with the permission of the copyright owner. The permission is granted within a nationwide license, supported by the German Research Foundation (abbr. in German DFG). www.nationallizenzen.de/ 6557467464 PMJ0010.1177/0269216316655746Palliative10.110.1177/0269216316655746177/0269216316655746Palliative MedicineGaertner et al. research-article2016 Review Article Palliative Medicine 2017, Vol. 31(1) 26 –34 Metamizole/dipyrone for the relief © The Author(s) 2016
    [Show full text]
  • Guideline for the Management of Knee and Hip Osteoarthritis Second Edition
    Guideline for the management of knee and hip osteoarthritis Second edition racgp.org.au Healthy Profession. Healthy Australia. Guideline for the management of knee and hip osteoarthritis. Second edition Disclaimer The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates. Whilst the text is directed to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices. Accordingly, The Royal Australian College of General Practitioners Ltd (RACGP) and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information.
    [Show full text]
  • Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis
    Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis: A Randomized Double Blind Controlled 3 Month Clinical Trial NORMAN M.R. THIE, NARASIMHA G. PRASAD, and PAUL W. MAJOR ABSTRACT. Objective. To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA). Methods. Forty women and 5 men received either GS (500 mg tid) or ibuprofen (400 mg tid) for 90 days in a randomized double blind study. Assessment: TMJ pain with function, pain-free, and volun- tary maximum mouth opening, Brief Pain Inventory (BPI) questionnaire and masticatory muscle tenderness were performed after a one week washout and at Day 90. Acetaminophen (500 mg) dispensed for breakthrough pain was counted every 30 days to Day 120. Results. In total, 176 adults were interviewed, 45 (26%) qualified, 39 (87%) completed the study (21 GS, 18 ibuprofen). Four discontinued due to stomach upset (3 ibuprofen, one GS), one due to dizzi- ness (GS), one due to inadequate pain control (ibuprofen). Within-group analysis revealed signifi- cant improvement compared to baseline of all variables in both treatment groups but no change in acetaminophen used. Fifteen GS (71%) and 11 ibuprofen (61%) improved, with positive clinical response taken as a 20% decrease in primary outcome (TMJ pain with function). The number of patients with positive clinical response was not statistically different between groups (p = 0.73). Between-group comparison revealed that patients taking GS had a significantly greater decrease in TMJ pain with function, effect of pain, and acetaminophen used between Day 90 and 120 compared with patients taking ibuprofen.
    [Show full text]
  • Efficacy and Safety of Diacerein And
    2012 iMedPub Journals Vol. 1 No. 1:5 Our Site: http://www.imedpub.com/ JOURNAL OF BIOMEDICAL SCIENCES doi: 10.3823/1004 Effi cacy and safety Navin Gupta2*, Somnath Datta1 of diacerein and 1 Assistant Professor 2 Marketing Lead, Bristol Correspondence: Department of Pharmacology, Mayers Squibb, Lower Parel, diclofenac in knee FOD, Jamia Millia Islamia, Mumbai * Department of Pharmacology, New Delhi Faculty of Dentistry, Jamia osteoarthritis in Millia Islamia, New Delhi1 Indian patients- Mobile: +91-9873150172 drgargmedico2002@ a prospective yahoo.co.in randomized open Running head: Diacerein versus diclofenac effects in patients of knee osteoar- label study thritis. Keywords: Osteoarthritis, Diacerein, Diclofenac, Visual analog scale, Western On- tario and McMaster Universities Osteoarthritis Index, Lequesne impairment index What is already known about this subject: Diclofenac is a well- known NSAID used in the management of pain in Osteoarthritis(OA). Diacerein is a slow acting, disease-modifying drug approved for OA. What this study adds: Diclofenac, diacerein as well as combination of the two improved the quality of life as compared to baseline. Diacerein has acceptable toxicity and long carry-over effect in osteoarthritis patients. Abstract Objectives: To determine the effi cacy and carryover effects of diacerein vs diclof- enac in Indian population with knee osteoarthritis (OA). Study design: After one week NSAID’s washout period, patients received either diacerein or diclofenac or combination for 12 weeks with 4 weeks follow-up to determine the carryover effects of the drugs. The primary effi cacy end point was the change from baseline in 100mm visual analog scale (VAS) score after 20 meters walk.
    [Show full text]
  • Efficacy and Safety of Diacerein in Patients with Inadequately
    1356 Diabetes Care Volume 40, October 2017 Efficacy and Safety of Diacerein Claudia R.L. Cardoso, Nathalie C. Leite, Fernanda O. Carlos, Andreia´ A. Loureiro, in Patients With Inadequately Bianca B. Viegas, and Gil F. Salles Controlled Type 2 Diabetes: A Randomized Controlled Trial Diabetes Care 2017;40:1356–1363 | https://doi.org/10.2337/dc17-0374 OBJECTIVE To assess, in a randomized, double-blind, and placebo-controlled trial, the efficacy and safety of diacerein, an immune modulator anti-inflammatory drug, in improving glycemic control of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Eighty-four patients with HbA1c between 7.5 and 9.5% (58–80 mmol/mol) were randomized to 48-week treatment with placebo (n = 41) or diacerein 100 mg/day (n = 43). The primary outcome was the difference in mean HbA1c changes during treatment. Secondary outcomes were other efficacy and safety measurements. A gen- eral linear regression with repeated measures, adjusted for age, sex, diabetes duration, and each baseline value, was used to estimate differences in mean changes. Both intention-to-treat (ITT) analysis and per-protocol analysis (excluding 10 patients who interrupted treatment) were performed. RESULTS Diacerein reduced HbA1c compared with placebo by 0.35% (3.8 mmol/mol; P =0.038) EMERGING TECHNOLOGIES AND THERAPEUTICS in the ITT analysis and by 0.41% (4.5 mmol/mol; P = 0.023) in the per-protocol analysis. The peak of effect occurred at the 24th week of treatment (20.61% [6.7 mmol/mol; P =0.014]and20.78% [8.5 mmol/mol; P = 0.005], respectively), but it attenuated fi fi toward nonsigni cant differences at the 48th week.
    [Show full text]
  • Clinical Study Protocol
    CLINICAL STUDY PROTOCOL COmparison of the effect of treatment with NSAIDs added to anti- TNF therapy versus anti-TNF therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis: a randomized controlled multicentre trial (CONSUL) Protocol number: CONSUL2016 Protocol version: 1.3 including Amendment No. 1 Date: 13.02.2017 EudraCT Number: 2016‐000615‐33 Investigational Products: Golimumab, Celecoxib Study Phase: phase IV Study Design: randomized, controlled, prospective, open-label, multicentrestudy Sponsor: Charité Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Germany Coordinating Investigator: Prof. Dr. med. Denis Poddubnyy Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie Campus Benjamin Franklin Charité Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin, Germany Tel: +49 30 8445-2302 or 450-514544 Fax: +49 30 8445-4149 Email: [email protected] Study Physician: Dr. med. Burkhard Muche -same address- Tel. +49 (30) 8445-4144 Email: [email protected] 4. CONSUL_Protocol_Version_1.3_with_Amendment_1_13.02.2017_clear.docx Page 1 of 61 TABLE OF CONTENT 1 LIST OF ABBREVIATIONS ................................................................................................. 4 2 PROTOCOL SYNOPSIS ..................................................................................................... 6 3 ASSESSMENT SCHEDULE .............................................................................................. 13 4 INTRODUCTION
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]